反应详情

The title compound was prepared following the procedure described for Example 94, but starting from 4-(5-(1-(2-fluorophenyl)-5-(pyridin-4-yl)-1H-1,2,3-triazol-4-yl)-1,2,4-oxadiazol-3-yl)benzaldehyde, obtained as described in Example 113, Step 1, (100 mg; 0.24 mmol) and 2-methoxyethanamine (36.4 mg; 0.48 mmol) to give Example 114 as a white solid. 1H NMR: (CDCl3, 400 MHz) δ 8.73-8.69 (2H, m), 8.05 (2H, d, J=8.0 Hz), 7.66-7.52 (2H, m), 7.46 (2H, d, J=8.0 Hz), 7.40-7.33 (3H, m), 7.18 (1H, t, J=9.1 Hz), 3.88 (2H, s), 3.53 (2H, t, J=5.1 Hz), 3.36 (3H, s), 2.82 (2H, t, J=5.1 Hz). LC/MS (Method C): 472 (M+H)+. HPLC (Method F) Rt 3.07 min (Purity: 96.5%).

1. customobtained